SiriusPoint Ltd. (SPNT) Stock Price & How to Invest

SiriusPoint was formed in 2021 when Third Point Reinsurance merged with Sirius International Insurance Group, and it now writes roughly $3.8 billion of gross premium a year across two segments, Insurance & Services and Reinsurance. The book spans about ten lines of business from four underwriting hubs, with accident and health the largest at roughly 27 percent of premium and general liability next at about 21 percent, and no other line above 10 percent. Alongside the underwriting operation sits International Medical Group, a travel and medical MGA that has been adding capability through bolt-on deals including Assist America in late 2025 and the World Nomads brand in early 2026. Headquarters are in Bermuda, staff numbers roughly 1,000, and the NYSE listing is the company's primary and only US listing.

For investors the picture is a repositioning that has largely already happened. Under CEO Scott Egan the company sold or ran off the volatile pieces, repurchased the entire $733 million stake held by former anchor shareholder CM Bermuda in February 2025, exited its 49 percent holding in Arcadian Risk Capital for about $140 million in January 2026, and steered new premium toward specialty insurance while deliberately letting reinsurance premium shrink. Second-quarter 2026 brought a 91.4 percent core combined ratio, a 13.8 percent operating return on equity, and the 21st consecutive quarter of favorable prior-year reserve development. At roughly $24 per share against $19.48 of book value per diluted share excluding AOCI, the market is paying a modest premium to book for a business targeting a 12 to 15 percent operating return across the cycle, with the debate centered on whether that return holds as property and casualty pricing softens.

Catastrophe and large-loss exposure has not disappeared, and a single heavy wind or wildfire season can erase a year of underwriting margin at a company of this size. Reserve development is the second exposure: the current streak of favorable releases is a strength today and a comparison problem later, since a company cannot release reserves indefinitely. Pricing across property catastrophe and much of casualty reinsurance has been drifting lower, which is precisely why premium is falling in that segment, and a longer soft market would pressure the 12 to 15 percent operating return target. Ownership is concentrated enough to matter, with entities associated with Daniel Loeb holding roughly 9.5 percent, and take-private speculation has circulated around the name before without a transaction ever being signed. Finally, the trailing headline earnings multiple near 6 times is flattered by non-recurring items including asset sales, so anyone anchoring on it is looking at a number the operating business does not repeat.

3 analysts publish price targets on SPNT, averaging $27.67 against a $24.25 price as of August 2026, or +14.1%. The published targets run from $25.00 to $31.00, a narrow spread, and the ratings split 2 buy, 2 hold, 0 sell. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SPNT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on SiriusPoint Ltd.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Specialty insurance replacing reinsurance in the mix. Insurance & Services gross written premium rose about 15 percent year over year to roughly $645 million in the second quarter of 2026, while Reinsurance premium fell about 9 percent to roughly $337 million. The most optimistic published target, $31.00, assumes this works close to its best case.

The case against. Catastrophe and large-loss exposure has not disappeared, and a single heavy wind or wildfire season can erase a year of underwriting margin at a company of this size. The most pessimistic target, $25.00, is roughly what SPNT is worth if this bites instead.

Read the full bull and bear case on SPNT, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see SiriusPoint Ltd.'s investor relations page or your broker.

• Gross premiums written (LTM): ~$3.8B
• Revenue (TTM): ~$3.0B
• Core combined ratio (Q2 2026): ~91.4%
• Book value per diluted share, ex-AOCI: ~$19.48
• Operating return on equity (H1 2026): ~14.7%
• Market capitalization: ~$2.8B at ~$24 per share

At roughly $24 the shares change hands near 1.2 times book value excluding AOCI, which is a modest premium for a carrier earning a mid-teens operating return. The trailing price to earnings ratio of roughly 6 is not a clean read, because trailing net income of about $495 million includes gains that will not recur; the forward multiple sits closer to 9. For an insurer, growth in book value per share plus capital returned is generally the more informative measure, and that combination ran at about 8 percent year to date through June alongside $295 million of buybacks.

Other names that sit close to SPNT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SPNT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SPNT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SPNT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

SiriusPoint is a small-cap specialty underwriter whose case rests on holding a combined ratio around 90 while book value per share compounds and the share count shrinks, not on any single quarter's premium line.

Whether SPNT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SPNT a buy or a sell?, and where the stock could go from here in the SPNT stock forecast.

For income investors, whether SPNT pays a dividend and how the payout looks is covered in does SPNT pay a dividend? And to weigh SPNT against a peer, read the full side-by-side comparisons: SPNT vs EG and SPNT vs RNR.